A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group

Subhalakshmi Sengupta; Uttara Chatterjee; Uma Banerjee; Samarendranath Ghosh; Sandip Chatterjee; Ashit K Ghosh

doi:10.4103/0971-5851.96965

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2012; 33(01): 25-31
DOI: 10.4103/0971-5851.96965

ORIGINAL ARTICLE

A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group

Subhalakshmi Sengupta

Department of Pathology, RG Kar Medical College, Kolkata, West Bengal, India

,

Uttara Chatterjee

Department of Pathology, IPGME and R, 244 AJC Bose Road, Kolkata, West Bengal, India

,

Uma Banerjee

Department of Pathology, Burdwan Medical College, Burdwan Town, District Burdwan, West Bengal, India

,

Samarendranath Ghosh

Department of Neurosurgery, Bangur Institute of Neurosurgery, Kolkata, West Bengal, India

,

Sandip Chatterjee

Park Children′s Center for Treatment and Research, 4 Gorky Terrace, Kolkata, West Bengal, India

,

Ashit K Ghosh

Department of Pathology, IPGME and R, 244 AJC Bose Road, Kolkata, West Bengal, India

› Institutsangaben

Abstract

als PDF herunterladen

Abstract

Objectives: The primary brain tumors are the second most common cause of death due to malignancies in children. This study was done to analyze the histological spectrum of primary brain tumors in children and also to find out the expression of p53 and Ki67 in some of the common pediatric brain tumors. Materials and Methods: This study was done over a period of 2.5 years. The patients were followed up until 6 months to determine the outcome. We examined H and E sections from 61 pediatric brain tumors and also performed immunohistochemical stains with p53 and Ki67 on 52 of these samples. Results: Of the 61 cases of pediatric brain tumors the commonest were pilocytic astrocytomas and medulloblastomas both constituting 22.9% of total cases, followed by high grade gliomas, that is, anaplastic astrocytoma and glioblastoma taken together (14.7%), diffuse astrocytomas (11.4%), ependymomas (8.1%), and oligodendrogliomas (4.9%). Other cases comprised craniopharyngiomas, astroblastomas, and gangliocytoma. The mean age of presentation was 9.3 years, male children being more commonly affected. Ki67 labeling index (LI) and p53 expression in pilocytic astrocytomas and diffuse astrocytomas were significantly lower than that of high-grade astrocytomas. However, there was no significant difference of expression of these two antigens in pilocytic astrocytomas and diffuse astrocytomas. It was found that Ki67 LI was a better marker for distinguishing between grades of astrocytoma than p53 (P=0.000 and P=0.002, respectively). The survival in cases of pilocytic astrocytomas was far better than high-grade gliomas. However, there was no significant difference in survival between pilocytic astrocytoma and diffuse infiltrating astrocytoma. There was significant positive correlation between expression of p53 and Ki67 LI in cases of medulloblastomas. Both p53 (P=0.002) and Ki67 LI (P=0.000) taken individually correlated well with survival in these cases. Also, Ki67 LI is better predictor of outcome than p53. Conclusion: From this study, it can be concluded that Ki67 and p53 score correlated well with the grade of astrocytoma; however, Ki67 is a better marker for differentiating between the grades of astrocytoma than p53. Also, Ki67 LI is a better prognostic factor than p53 in case of medulloblastomas.

Keywords

Pediatric brain tumors - p53 - Ki67

PDF (4086 kb)

Referenzen

References
1 Bunin G. What causes childhood brain tumors? Limited knowledge, many clues. Pediatric Neurosurg 2000;32:321-6.
2 Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human central nervous system. Mol Carcinog 1993;8:74-80.
3 Bhattacharjee MB, Bruner JM. p53 protein in pediatric malignant astrocytomas: A study of 21 patients. J Neurooncol 1997;32:225-33.
4 Kumar R. Scenario of pediatric CNS tumors in India. JK Sci 2006;8:190-2.
5 Chan GC. Recent advances in childhood brain tumours. HK J Paediatr 2006;11:3-12.
6 Tobias J, Hayward RD. Brain and spinal cord tumors in children. In: Thomas DG, editor. Neuro-oncology: Primary malignant brain tumors. Baltimore: The Johns Hopkins University Press; 1990. p. 164-92.
7 Grotzer MA, Janss AJ, Fung KM, Biegel JA, Sutton LN, Rorke LB, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-30.
8 Ho DM, Wong TT, Hsu CY, Ting LT, Chiang H. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: A study of 101 cases. Cancer 1998;82:2459-66.
9 Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, Forsyth PA, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53.
10 Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53.
11 Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 1998;33:446-52.
12 Sarkar C, Pramanik P, Karak AK, Mukhopadhyay P, Sharma MC, Singh VP, et al. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J Neuro Oncol 2002;59 : 49-61.
13 Shim KW, Joo SY, Kim SH, Choi JU, Kim DS. Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray. J Neurosurg Pediatr 2008;1:196-205.
14 Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, et al. Pediatric medulloblastoma: Prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neuro Oncol 1999;45:103-10.
15 Litofsky NS, Hinton D, Raffel C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 1994;34:967-73.
16 Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-36.
17 Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249-59.
18 Sure U, Rüedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, et al. Determination of p53 Mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas . J Neuropathol Exp Neurol 1997;56:7829
19 Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol 1999;9:463-7.
20 Suri V, Das P, P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: A histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80.
21 Ahmed R, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, et al. Alteration of the p53 gene in human gliomas. Cancer Res 1994;54:1324-30.
22 Woodburn RT, Azzarelli B, Montebello JF, Goss IE. Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol2001;52:57-62.
23 Jaros E, Lunec J, Perry RH, Kelly PJ, Pearson AD. P53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 1993;68:801-7
24 Ertan Y, Sezak M, Demirað B, Kantar M, Cetingül N, Turhan T, et al. Medulloblastoma: Clinicopathologic evaluation of 42 pediatric cases. Child Nerv Syst 2009;25:353-6.
25 Tihan T, Davis R, Elowitz E, DiCostanzo D, Moll U. Practical value of Ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab Med 2000;124:108-13.